Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pradeep Nagaraju

Urogynecology and Reconstructive Pelvic Surgery Royal Oak, MI Medical Doctor

NPI 1285615583 CMS profile 240093

3535 W 13 Mile Rd, Suite 407, Royal Oak, MI 48073

Open in the dashboard

General payments

$4,667

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pradeep Nagaraju of Royal Oak, MI is reported in the CMS Open Payments database as having received $4,667 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $561 20
2024 General $1,123 35
2023 General $818 20
2022 General $723 23
2021 General $152 9
2020 General $224 5
2019 General $1,065 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pradeep Nagaraju
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Pradeep Nagaraju were reported at $561. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Pradeep Nagaraju Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $1,065 $799 $319–$2,013 $163
2020 $224 $384 $158–$1,360 $114
2021 $152 $641 $247–$2,515 $132
2022 $723 $843 $347–$2,794 $149
2023 $818 $819 $308–$2,302 $160
2024 $1,123 $882 $306–$2,459 $164
2025 $561 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $524 7 payments
  2. Boston Scientific Corporation $490 5 payments
  3. Ferring Pharmaceuticals Inc. $430 7 payments
  4. AbbVie, Inc. $365 22 payments
  5. Caldera Medical, Inc $361 3 payments
  6. Medtronic USA, Inc. $292 3 payments
  7. Axonics Modulation Technologies, Inc. $259 4 payments
  8. Sumitomo Pharma America, Inc. $228 12 payments
  9. Teleflex LLC $158 2 payments
  10. NeoTract Inc. $157 2 payments
  11. Other $1,404 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,638 140 payments
  2. Education $29 2 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM $524 7 payments
  2. FIRMAGON $392 5 payments
  3. Desara $361 3 payments
  4. UROLIFT $316 4 payments
  5. GEMTESA $311 18 payments
  6. BOTOX $255 15 payments
  7. Axonics $237 3 payments
  8. General - Female SUI $170 1 payment
  9. INTERSTIM ICON $153 1 payment
  10. Upsylon $148 1 payment
  11. Other $2,404 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

3,973

Median for Urology: 1,053

Drug cost

$346,658

Median for Urology: $101,464

Branded share of claims

27.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 113 $110,087
Gemtesa Vibegron Brand 116 $95,565
Mirabegron Er Mirabegron Brand 33 $24,515
Tamsulosin Hcl Generic 1,133 $21,297
Trospium Chloride Generic 138 $13,116
Methenamine Hippurate Generic 182 $12,586
Finasteride Generic 491 $9,494
Solifenacin Succinate Generic 215 $9,427
Estradiol Generic 129 $9,017
Tolterodine Tartrate Er Tolterodine Tartrate Brand 59 $7,211

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$383,065

Of which drugs: $76,464

Medicare patients

1,173

Average age 75

Services billed

8,081

567 women, 606 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 36%
Diabetes 32%
Chronic kidney disease 28%
Atrial fibrillation 23%
Depression 20%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Bcg live intravesical instillation, 1 mg J9030 Office 16 1,200 $2,729
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 17 28 $57

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $160
$160 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $98
$98 116 —
ELIGARD
  • TOLMAR, INC. $42
$42 — —
JATENZO
  • TOLMAR, INC. $25
$25 — —
XYOSTED
  • Antares Pharma, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record